<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ital J Pediatr</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ital J Pediatr</journal-id>
      <journal-title-group>
        <journal-title>Italian Journal of Pediatrics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1824-7288</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24044622</article-id>
      <article-id pub-id-type="pmc">3849883</article-id>
      <article-id pub-id-type="publisher-id">1824-7288-39-59</article-id>
      <article-id pub-id-type="doi">10.1186/1824-7288-39-59</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Nijmegen breakage syndrome and chronic polyarthritis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Pasic</surname>
            <given-names>Srdjan</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>pasics@ikomline.net</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Cupic</surname>
            <given-names>Maja</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>mcupic@med.bg.ac.rs</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Jovanovic</surname>
            <given-names>Tanja</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>tjovanovic@med.bg.ac.rs</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Djukic</surname>
            <given-names>Slobodanka</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>sdjukic@med.bg.ac.rs</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Kavaric</surname>
            <given-names>Maja</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>maja.kavaric@kccg.me</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Lazarevic</surname>
            <given-names>Ivana</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>ilazarevic@med.bg.ac.rs</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Pediatric Immunology, Mother and Child Health Institute, Medical Faculty, University of Belgrade, 8 R. Dakica Street, Belgrade 11070, Serbia</aff>
      <aff id="I2"><label>2</label>Institute for Microbiology and Immunology, Medical Faculty, University of Belgrade, Belgrade, Serbia</aff>
      <aff id="I3"><label>3</label>Department of Hematology, Institute for diseases in childhood Clinical center of Montenegro, Podgorica, Montenegro</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>9</month>
        <year>2013</year>
      </pub-date>
      <volume>39</volume>
      <fpage>59</fpage>
      <lpage>59</lpage>
      <history>
        <date date-type="received">
          <day>4</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>9</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 Pasic et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Pasic et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.ijponline.net/content/39/1/59"/>
      <abstract>
        <p>We report on pediatric patient with Nijmegen breakage syndrome (NBS), a rare DNA repair disorder characterized by microcephaly, immunodeficiency and predisposition to malignant lymphomas, who developed juvenile idiopathic arthritis (JIA)-like polyarthritis. In patients with primary immunodeficiencies (PID), septic arthritis due to pyogenic bacteria or mycoplasmal arthritis are the most common osteoarticular manifestations. In certain PID, chronic, non-infectious arthritis resembling rheumatoid arthritis may occur. In our patient microbiologic cultures of synovial fluid including <italic>Mycoplasma spp</italic>. were negative. At first, because of suspected mycoplasmal arthritis we used macrolides and doxycycline combined with hydroxychloroquine but without therapeutic response. However, the use of rituximab led to remission of her polyarthritis lasting for 9&#xA0;months. Autoimmune features were rarely reported in NBS. An occurrence of JIA-like, chronic polyarthritis in NBS, a DNA repair disorder characterized by decreased tolerance of immunosuppressive drugs such as methotrexate and a high natural risk for lymphomas, makes therapeutic approach even more complex.</p>
      </abstract>
      <kwd-group>
        <kwd>Nijmegen breakage syndrome</kwd>
        <kwd>Juvenile idiopathic arthritis</kwd>
        <kwd>Polyarthritis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Nijmegen breakage syndrome (NBS) is a rare autosomal recessive DNA repair disorder characterized by microcephaly, immunodeficiency and cancer [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. NBS is due to hypomorphic mutations of <italic>NBS1</italic> gene, encoding less functional nibrin, a protein involved in the repair of DNA double-strand breaks and in cell cycle checkpoints [<xref ref-type="bibr" rid="B3">3</xref>]. Albeit NBS has been reported in different ethnic groups, more than 90% of affected persons are of Slavic origin (Central-East Europe) and they carry homozygous founder mutation, a 5- base-pair deletion 657del5 [<xref ref-type="bibr" rid="B4">4</xref>].</p>
      <p>In NBS, congenital osteoarticular malformations such as clinodactyly, polydactyly or syndactyly are the most common occuring in one-half of the patients. Hydronephrosis, hypoplastic kidney, anal atresia/stenosis, CNS malformations or gonadal failure are less commonly observed [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>].</p>
      <p>In several other primary immunodeficiencies (PID) non-infectious, chronic polyarthritis resembling rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA) has been reported [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>].</p>
      <p>We report a JIA-like, chronic polyarthritis in a female patient with NBS.</p>
    </sec>
    <sec>
      <title>Case report</title>
      <p>This 12-year-old girl of Slavic origin is the first child of healthy, unrelated parents. During neonatal period intrauterine growth retardation (birth weight, 2700 grams) and microcephaly (head circumference, HC&#x2009;=&#x2009;31&#xA0;cm; &lt;&#x2009;p3) were observed. Her past medical history revealed that she suffered from recurrent lung infections (otitis media, pneumonia) since infancy. At 18&#xA0;months of age she was treated for bacterial meningitis. At 8&#xA0;years of age she was hospitalized because of severe varicella complicated with pneumonia. At the same age she had an episode of hip pain diagnosed as transitory synovitis.</p>
      <p>At 9&#xA0;years of age she was referred to our Institute for investigation of repeated lung infections. Physical examination on admission included: height, 129&#xA0;cm (p50) and the body weight, 29&#xA0;kg (p50); microcephaly (head circumference&#x2009;=&#x2009;46&#xA0;cm, &lt;&#x2009;p3); typical facial features with prominent midface, large ears and hyperthelorism with upward slant of the palpebral fissures (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>); hypopigmented spots on trunk and extremities; bilateral clinodactyly and syndactyly of the second and third toe were observed. Chest examination revealed bilateral basilar crackles due to bronchiectasis. Neurological examination and ophtalmologic slit-lamp examination were normal.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Microcephaly and typical bird-like appearance in our patient.</p>
        </caption>
        <graphic xlink:href="1824-7288-39-59-1"/>
      </fig>
      <p>Immunologic investigations are presented in Table&#xA0;<xref ref-type="table" rid="T1">1</xref>. Karyotype of peripheral blood lymphocytes revealed typical chromosomal rearrangements involving chromosomes 7 and 14. Final diagnosis of NBS was established by mutation analysis of the <italic>NBS1</italic> gene that revealed homozygousity for typical 5 base-pair deletion (657del5). She was placed on regular substitution with intravenous immunoglobulin (IVIG) in a dose of 400 milligrams/kg/body weight every 4&#xA0;weeks. With this treatment acute exacerbations of her chronic lung disease decreased in frequency.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Immunologic investigations in our patent</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">&#xA0;</th>
              <th align="center">
                <bold>At diagnosis</bold>
              </th>
              <th align="center">
                <bold>At the onset of arthritis</bold>
              </th>
              <th align="center">
                <bold>Normal values for given age</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">IgA (g/l)<hr/></td>
              <td align="center" valign="bottom">0.08<hr/></td>
              <td align="center" valign="bottom">0.07<hr/></td>
              <td align="center" valign="bottom">0.11-2.51<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">IgM<hr/></td>
              <td align="center" valign="bottom">0.04<hr/></td>
              <td align="center" valign="bottom">0.06<hr/></td>
              <td align="center" valign="bottom">0.13-2.51<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">IgG<hr/></td>
              <td align="center" valign="bottom">0.70<hr/></td>
              <td align="center" valign="bottom">10.8<sup>b</sup><hr/></td>
              <td align="center" valign="bottom">6.54-15.94<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">IgE (IU/ml)<hr/></td>
              <td align="center" valign="bottom">&lt; 50<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">&#xA0;<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Absolute lymphocyte count (mm<sup>3</sup>)<hr/></td>
              <td align="center" valign="bottom">1512<hr/></td>
              <td align="center" valign="bottom">1340<hr/></td>
              <td align="center" valign="bottom">1100-5900<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CD3+ lymphocytes<hr/></td>
              <td align="center" valign="bottom">726<hr/></td>
              <td align="center" valign="bottom">650<hr/></td>
              <td align="center" valign="bottom">700-4200<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CD4+<hr/></td>
              <td align="center" valign="bottom">333<hr/></td>
              <td align="center" valign="bottom">252<hr/></td>
              <td align="center" valign="bottom">300-2000<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CD8+<hr/></td>
              <td align="center" valign="bottom">348<hr/></td>
              <td align="center" valign="bottom">396<hr/></td>
              <td align="center" valign="bottom">300-1800<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CD19+<hr/></td>
              <td align="center" valign="bottom">36<hr/></td>
              <td align="center" valign="bottom">42<hr/></td>
              <td align="center" valign="bottom">200-1600<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CD3-CD16&#x2009;+&#x2009;C56+ (NK-cells<sup>a</sup>)<hr/></td>
              <td align="center" valign="bottom">665<hr/></td>
              <td align="center" valign="bottom">720<hr/></td>
              <td align="center" valign="bottom">9-900<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Proliferative lymphocyte response using phytohemagglutinin (PHA)<hr/></td>
              <td align="center" valign="bottom">Pt. SI<sup>c</sup> 18&#xD7;<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
              <td align="center" valign="bottom">-<hr/></td>
            </tr>
            <tr>
              <td align="left">&#xA0;</td>
              <td align="center">Control SI 87&#xD7;</td>
              <td align="center">&#xA0;</td>
              <td align="center">&#xA0;</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p><sup>a</sup> NK-cells &#x2013; natural killer; <sup>b</sup> IgG trough level during replacement therapy with IVIG; <sup>c</sup><italic>SI</italic> stimulation index.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>At 10&#xA0;years of age she was admitted because of pain, morning stiffness and bilateral swelling of her proxymal interphalangeal (PIP), wrist and knee joints (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>). Affected joints were hot, swollen and tender on passive or active motion. L Laboratory investigations at that time included: erythrocyte sedimentation rate 42&#xA0;mm/hr, C-reactive protein 92&#xA0;mg/l (normal&#x2009;&lt;&#x2009;5&#xA0;mg/l), hemoglobin 121&#xA0;g/l, WBC count 6.2 &#xD7;&#x2009;10<sup>9</sup>/l with 58% of neutrophils, 30% of lymphocytes and 6% of monocytes, platelets were 346 &#xD7; 10<sup>9</sup>/l; urinalysis was normal; liver function tests was normal; serum lactate-dehydrogenase was not increased; serum concentrations of complement components C3, 1.99&#xA0;g/l and C4, 0.46&#xA0;g/l both were increased. Immunologic investigations including serum immunoglobulin concentrations, peripheral blood lymphocyte phenotype and proliferative response of lymphocytes to mitogen are presented in Table&#xA0;<xref ref-type="table" rid="T1">1</xref>. Antinuclear antibodies, anti-double stranded DNA, anti-cyclic citrullinated protein antibodies and rheumatoid factor (RF) were all negative.</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Symmetrical arthritis of proximal interphalangeal, metacarpophalangeal and radiocarpal joints (also, note vitiligo).</p>
        </caption>
        <graphic xlink:href="1824-7288-39-59-2"/>
      </fig>
      <p>Diagnostic puncture of knee joint was done and 4 milliliters of cloudy, yellow sinovial exudate was obtained. Microscopic examination and bacterial culture of joint fluid specimen yielded no microogranism. Also, special cultures for <italic>Mycoplasma spp., Ureaplasma urealyticum</italic> and mycobacteria were negative.</p>
      <p>An initial treatment included non-steroidal anti-inflammatory drug (NSAID) meloxicam together with azithromycin because of suspected mycoplasmal infection. After two months of treatment, no improvement was seen so that azithromycin was replaced for doxycycline in a daily dose of 4&#xA0;mg/kg/body weight and with this treatment her joint symptoms transiently improved. However, over the next 6&#xA0;months several relapses of arthritis were observed so hydroxychloroquine as disease-modifying antirheumatic drug (DMARD) was given.</p>
      <p>After one year of treatment no objective improvement of polyarthritis using defined core set of six variables for JIA (physician global assessment of disease activity; parent global assessment of disease activity; number of joints with active arthritis; number of joints with limited range of motion; child health assessment questionaiire, erythrocyte sedimentation rate) was observed [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p>
      <p>We decided to introduce rituximab in a standard dose regimen (375&#xA0;mg/m<sup>2</sup>/month) used in children and adults affected with PID who developed autoimmune diseases [<xref ref-type="bibr" rid="B10">10</xref>]. She received six infusions of rituximab without major side-effects and continued to receive regular IVIG therapy. Treatment with rituximab led to complete clinical and laboratory remission of her polyarthritis lasting for 9&#xA0;months (Table&#xA0;<xref ref-type="table" rid="T2">2</xref>).</p>
      <table-wrap position="float" id="T2">
        <label>Table 2</label>
        <caption>
          <p>Assessment of disease activity using six defined variables</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Assessment of disease activity</bold>
              </th>
              <th align="center">
                <bold>Before rituximab</bold>
              </th>
              <th align="center">
                <bold>After rituximab</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">Physician VAS<hr/></td>
              <td align="center" valign="bottom">68<hr/></td>
              <td align="center" valign="bottom">10<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Parental VAS<hr/></td>
              <td align="center" valign="bottom">73<hr/></td>
              <td align="center" valign="bottom">8<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">N of joints with active arthritis<hr/></td>
              <td align="center" valign="bottom">15<hr/></td>
              <td align="center" valign="bottom">0<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">N of joints with limited range of motion<hr/></td>
              <td align="center" valign="bottom">12<hr/></td>
              <td align="center" valign="bottom">3<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CHAQ<hr/></td>
              <td align="center" valign="bottom">2.25<hr/></td>
              <td align="center" valign="bottom">1.25<hr/></td>
            </tr>
            <tr>
              <td align="left">Erythrocyte sedimentation rate (mm/hr)</td>
              <td align="center">80</td>
              <td align="center">12</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Microcephaly, immunodeficiency and predisposition for lymphoma at an early age are the hallmarks of NBS [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Other commonly associated features in NBS include skin manifestations such as caf&#xE9;-au-lait spots, vitiligo, telangiectasia, flat haemangiomas or sun sensitivity of the eyelids [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Also, congenital malformations such as clinodactyly or syndactyly of the II/III toes are common occuring in one-half of the patients.</p>
      <p>Inflammatory, JIA-like polyarthritis has been reported so far in the single Argentinian patient of Hungarian origin with NBS [<xref ref-type="bibr" rid="B11">11</xref>]. Similar to our patient, in Argentinian patient the course of arthritis resembled polyarticular onset JIA, symmetrically affecting small and large joints.</p>
      <p>In humoral PID, such as X-linked agammaglobulinaemia (XLA) or common variable immunodeficency (CVID), septic arthritis caused with pyogenic bacteria (<italic>S.aureus, S.pneumoniae, H.influenzae type b</italic>) is the most common osteoarticular manifestation [<xref ref-type="bibr" rid="B12">12</xref>]. Infectious arthritis in patients with humoral PID may be also caused with <italic>Mycoplasma spp</italic>. and <italic>U.urealyticum</italic>[<xref ref-type="bibr" rid="B12">12</xref>]. Colonisation of mycoplasmal species in these patients is facilitated because of the lack of secretory antibodies at mucosal surfaces, and these organisms easily spread to synovial fluid. Also, patients with XLA or CVID may remain susceptible to mycoplasmal infection even after introduction of regular IVIG therapy because commercial IVIG lots do not contain sufficient titers of specific antibodies against <italic>Mycoplasma spp</italic>.</p>
      <p>In patients with PID, differentiating non-infectious arthritis from mycoplasmal infection represents a problem, because culturing of these microorganisms may be difficult. In originally reported patient with NBS and polyarthritis analysis of synovial fluid was not done [<xref ref-type="bibr" rid="B11">11</xref>]. Furr <italic>et al.</italic> reported mycoplasmal infection in 8 (38%) of 23 patients with hypogammaglobulinaemia and arthritis [<xref ref-type="bibr" rid="B13">13</xref>]. In our patient analysis of synovial fluid showed characteristics of exudate but microbiologic investigations was negative. At first, we treated our patient with macrolides and doxycycline but without therapeutic response.</p>
      <p>In a subset of patients with NBS, similar to CVID, immunodeficiency is characterized with lymphopenia associated with a state of &#x201C;immune dysregulation&#x201D; leading to autoimmunity [<xref ref-type="bibr" rid="B14">14</xref>]. Opposite to CVID, autoimmune disorders such as autoimmune hemolytic anemia, thrombocytopenia or polyarthritis were rarely reported in NBS [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. In approximately 20% of patients with CVID, a spectrum of autoimmune disorders can arise, with autoimmune cytopenias being the most common, followed with RA, pernicious anemia, primary biliary cirrhosis, thyroiditis, sicca syndrome, systemic lupus or inflammatory bowel disease, respectively [<xref ref-type="bibr" rid="B15">15</xref>]. In a subset of patients with granulomatous form of CVID characterized with lymphopenia, autoimmune disorders, including rheumatoid-like arthritis, were even more common, occurring in more than one-half of patients [<xref ref-type="bibr" rid="B7">7</xref>]. In CVID, low proportions of CD4&#x2009;+&#x2009;CD25+, Foxp3 T regulatory cell subset correlated with presence of autoimmunity and splenomegaly [<xref ref-type="bibr" rid="B16">16</xref>]. In patients with NBS regulatory T cells so far were not investigated.</p>
      <p>In our patient the use of NSAID and hydroxychloroquine led to short-term improvement of arthritis. Hydroxychloroquine was the most commonly used in patients with CVID who developed rheumatoid-like arthritis or systemic lupus [<xref ref-type="bibr" rid="B7">7</xref>]. In a few patients with PID presenting with non-infectious arthritis an introduction of regular IVIG therapy was effective controlling articular symptoms [<xref ref-type="bibr" rid="B12">12</xref>]. By contrast, our and originally reported patient both experienced relapses of severe polyarthritis while receiving regular treatment with IVIG [<xref ref-type="bibr" rid="B11">11</xref>].</p>
      <p>In CVID, cautious use of steroids has been employed for treatment of various autoimmune features including arthritis [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Rosenzweig <italic>et al.</italic> also observed an initial improvement of JIA-like arthritis in NBS patient using prednisone [<xref ref-type="bibr" rid="B11">11</xref>]. We were reluctant to commence steroids because of the risk for severe infections. The use of low-dose methotrexate, a DMARD with well established safety and efficacy in children with JIA, was considered in Argentinian patient with NBS [<xref ref-type="bibr" rid="B11">11</xref>]. However, previously reported patients with NBS treated for malignancy showed reduced tolerance to methotrexate, alkylating agents, epipodophilotoxines and anthracyclines [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. Therefore, we believe that prolonged use of methotrexate would not be a safe option in NBS patients with arthritis.</p>
      <p>Anti-TNF agents are widely accepted treatment for patients with JIA who not respond to treatment with DMARD&#x2019;s. However, the use of anti-TNF or anti-TNF receptor recombinant fusion monoclonal antibodies (infliximab, etanercept) should be avoided in NBS because of already present high risk for lymphoma.</p>
      <p>In our patient an improvement of arthritis was observed after the use of rituximab. Because of profound immunodeficiency we did not use rituximab in a high-dose regimen recommended for treatment of rheumatoid arthritis but instead we employed standard dosage (375&#xA0;mg/m<sup>2</sup>) that was safely used in PID. In XLA, a condition with total absence of mature B cells, occurence of RA has been rarely reported [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. This observation led to B cell depletion approach with humanized monoclonal antibody rituximab in several rheumatic diseases. In PID, the mechanism of inflammatory, non-infectious arthritis is not well understood. However, in patients with PID and severe, chronic arthritis, depletion of synovial B cells serving as antigen presenting cells to autoreactive T cell clones may be important [<xref ref-type="bibr" rid="B21">21</xref>].</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>In conclusion, we report on second pediatric patient with NBS who developed chronic, JIA-like polyarthritis. Non-infectious, chronic polyarthritis resembling JIA or RA was the most commonly associated with antibody deficiencies. An occurrence of inflammatory polyarthritis in NBS represents a rare, autoimmune feature in this DNA repair disorder.</p>
    </sec>
    <sec>
      <title>Note added in proof</title>
      <p>At the age of 15&#xA0;years our patient developed T-cell lymphoblastic leukemia/lymphoma (TLBL/ALL) and started treatment according to the protocol (Berlin-Frankfurth-M&#xFC;nster, BFM&#x2019;09 protocol) for standard risk ALL.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the parents for the publication of this report and any accompanying images.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>NBS: Nijmegen breakage syndrome; JIA: Juvenile idiopathic arthritis; RA: Rheumatoid arthritis; PID: Primary immunodeficiency; CVID: Common variable immunodeficiency; IVIG: Intravenous immunoglobulin; DMARD: Disease-modifying antirheumatic drug.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contribution</title>
      <p>SP, MC, IJ, SD, MK and TJ drafted the manuscript. SP make a critical revision. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgement</title>
      <p>This manuscript is partially funded through the grants (No. 175073 to SP, MC, IL and TJ; No. 175065 to SP) Ministry of Science and Technology, Republic of Serbia.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Weemaes</surname>
            <given-names>CMR</given-names>
          </name>
          <name>
            <surname>Hustinx</surname>
            <given-names>TWJ</given-names>
          </name>
          <name>
            <surname>Scheres</surname>
            <given-names>JMJC</given-names>
          </name>
          <article-title>A new chromosomal instability disorder: Nijmegen breakage syndrome</article-title>
          <source>Acta Paediatr Scand</source>
          <year>1981</year>
          <volume>70</volume>
          <fpage>557</fpage>
          <lpage>564</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1651-2227.1981.tb05740.x</pub-id>
          <pub-id pub-id-type="pmid">7315300</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <collab>International Nijmegen breakage syndrome study group</collab>
          <article-title>Nijmegen breakage syndrome</article-title>
          <source>Arch Dis Child</source>
          <year>2000</year>
          <volume>82</volume>
          <fpage>400</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1136/adc.82.5.400</pub-id>
          <pub-id pub-id-type="pmid">10799436</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Varon</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Vissinga</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Platzer</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Nibrin, a novel DNA double-break strand protein is mutated in Nijmegen breakage syndrome</article-title>
          <source>Cell</source>
          <year>1998</year>
          <volume>93</volume>
          <fpage>467</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81174-5</pub-id>
          <pub-id pub-id-type="pmid">9590180</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chrzanowska</surname>
            <given-names>KH</given-names>
          </name>
          <name>
            <surname>Hanna Gregorek</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Dembowska-Bagi&#x144;ska</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kalina</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Digweed</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Nijmegen breakage syndrome</article-title>
          <source>Orphanet J Rare Diseases</source>
          <year>2012</year>
          <volume>7</volume>
          <fpage>13</fpage>
          <pub-id pub-id-type="doi">10.1186/1750-1172-7-13</pub-id>
          <pub-id pub-id-type="pmid">22373003</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hansel</surname>
            <given-names>TT</given-names>
          </name>
          <name>
            <surname>Haeney</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>RA</given-names>
          </name>
          <article-title>Primary hypogammaglobulinaemia and arthritis</article-title>
          <source>Br Med J</source>
          <year>1987</year>
          <volume>295</volume>
          <fpage>174</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.1136/bmj.295.6591.174</pub-id>
          <pub-id pub-id-type="pmid">3115363</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cunningham-Rundles</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bodian</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Common variable immunodeficiency: clinical and immunological features of 248 patients</article-title>
          <source>Clin Immunol</source>
          <year>1999</year>
          <volume>92</volume>
          <fpage>34</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1006/clim.1999.4725</pub-id>
          <pub-id pub-id-type="pmid">10413651</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ardeniz</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Cunningham-Rundles</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Granulomatous disease in common variable immunodeficiency</article-title>
          <source>J Aller Clin Immunol</source>
          <year>2009</year>
          <volume>133</volume>
          <fpage>198</fpage>
          <lpage>207</lpage>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Giannini</surname>
            <given-names>EH</given-names>
          </name>
          <name>
            <surname>Ruperto</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ravelli</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lovell</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Felson</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Martini</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Preliminary definition of improvement in juvenile arthritis</article-title>
          <source>Arthr Rheum</source>
          <year>1997</year>
          <volume>40</volume>
          <fpage>1202</fpage>
          <lpage>1209</lpage>
          <pub-id pub-id-type="pmid">9214419</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Susic</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ruperto</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Stojanovic</surname>
            <given-names>R</given-names>
          </name>
          <article-title>The Serbian version of The Child Health Assessment Questionnaire (CHAQ) and Child Health Questionnaire (CHQ)</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2001</year>
          <volume>19</volume>
          <issue>4Suppl.23</issue>
          <fpage>S168</fpage>
          <lpage>S172</lpage>
          <pub-id pub-id-type="pmid">11510324</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gobert</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bussel</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Cunningham-Rundles</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients</article-title>
          <source>Br J Haematol</source>
          <year>2011</year>
          <volume>155</volume>
          <fpage>498</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2011.08880.x</pub-id>
          <pub-id pub-id-type="pmid">21981575</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rosenzweig</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Russo</surname>
            <given-names>RAG</given-names>
          </name>
          <name>
            <surname>Gallego</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zelasko</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Juvenile rheumatoid arthritis-like arthritis in Nijmegen breakage syndrome</article-title>
          <source>J Rheumatol</source>
          <year>2001</year>
          <volume>28</volume>
          <fpage>2548</fpage>
          <lpage>2550</lpage>
          <pub-id pub-id-type="pmid">11708432</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bloom</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Cunningham-Rundles</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Osteoarticular infectious complications in patients with primary immunodeficiencies</article-title>
          <source>Curr Opin Rheumatol</source>
          <year>2008</year>
          <volume>20</volume>
          <fpage>480</fpage>
          <lpage>485</lpage>
          <pub-id pub-id-type="doi">10.1097/BOR.0b013e3282fd6e70</pub-id>
          <pub-id pub-id-type="pmid">18525364</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Furr</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Taylor-Robinson</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Webster</surname>
            <given-names>AD</given-names>
          </name>
          <article-title>Mycoplasma and Ureaplasma infection in patients with hypogammaglobulinaemia and their role in arthritis: microbiologic observations over twenty years</article-title>
          <source>Ann Rheum Dis</source>
          <year>1984</year>
          <volume>42</volume>
          <fpage>108</fpage>
          <lpage>110</lpage>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Michalkiewitz</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Barth</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chrzanowska</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Abnormalities in T and NK lymphocyte phenotype in patients with Nijmegen breakage syndrome</article-title>
          <source>Clin Exp Immunol</source>
          <year>2003</year>
          <volume>134</volume>
          <fpage>482</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2249.2003.02285.x</pub-id>
          <pub-id pub-id-type="pmid">14632755</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Agraval</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Cunningham-Rundles</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Autoimmunity and common variable immunodeficiency</article-title>
          <source>Curr Allergy Asthma Rep</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>347</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1007/s11882-009-0051-0</pub-id>
          <pub-id pub-id-type="pmid">19671377</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fevang</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Yndestad</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sandberg</surname>
            <given-names>WJ</given-names>
          </name>
          <article-title>Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2007</year>
          <volume>147</volume>
          <fpage>521</fpage>
          <lpage>525</lpage>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Seidemann</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Henze</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Beck</surname>
            <given-names>JD</given-names>
          </name>
          <article-title>Non-Hodgkin&#x2019;s lymphoma in patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials</article-title>
          <source>Ann Oncol</source>
          <year>2000</year>
          <volume>11</volume>
          <issue>Suppl.1</issue>
          <fpage>S141</fpage>
          <lpage>S145</lpage>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Barth</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Demori</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Pecile</surname>
            <given-names>V</given-names>
          </name>
          <article-title>Anthracyclines in Nijmegen breakage syndrome</article-title>
          <source>Med Pediatr Oncol</source>
          <year>2003</year>
          <volume>40</volume>
          <fpage>122</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1002/mpo.10079</pub-id>
          <pub-id pub-id-type="pmid">12461799</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hermaszewski</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ratnavel</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Webster</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Denman</surname>
            <given-names>AM</given-names>
          </name>
          <article-title>Rheumatoid arthritis in a patient with primary hypogammaglobulinaemia</article-title>
          <source>Br J Rheumatol</source>
          <year>1993</year>
          <volume>32</volume>
          <fpage>636</fpage>
          <lpage>639</lpage>
          <pub-id pub-id-type="doi">10.1093/rheumatology/32.7.636</pub-id>
          <pub-id pub-id-type="pmid">8339142</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Verbruggen</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>De Backer</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Deforce</surname>
            <given-names>D</given-names>
          </name>
          <article-title>X-linked agammaglobulinemia and rheumatoid arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>44</volume>
          <fpage>1075</fpage>
          <lpage>1078</lpage>
          <pub-id pub-id-type="pmid">15564308</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Thurlings</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Vos</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wijbrandts</surname>
            <given-names>CA</given-names>
          </name>
          <article-title>Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response</article-title>
          <source>Ann Rheum Dis</source>
          <year>2008</year>
          <volume>67</volume>
          <fpage>917</fpage>
          <lpage>925</lpage>
          <pub-id pub-id-type="pmid">17965121</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
